Insider · CIK 0001943192
Christopher R. Cline
cfoofficer
Files at TVTX (Travere Therapeutics, Inc.). First filing Jan 23, 2025, latest Sep 17, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 8
$0 bought, $3.4M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TVTX: Travere Therapeutics, Inc.
TVTXOct 9, 2026 · close 52.13
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Travere Therapeutics, Inc. | $3.1M 50,508 shares | -37% | +175% from low-7% from high | |
| 43Moderate | Travere Therapeutics, Inc. | $43k 642 shares | -1% | +270% from low-0% from high | |
| 2Weak | Travere Therapeutics, Inc. | $11k 573 shares | -1% | +60% from low-17% from high | |
| 2Weak | Travere Therapeutics, Inc. | $8,136 470 shares | -1% | +42% from low-27% from high | |
| 28Weak | Travere Therapeutics, Inc. | $38k 1,784 shares | -2% | +75% from low-10% from high | |
| 22Weak | TVTXsell Travere Therapeutics, Inc. | $631 48 shares | -0% | +18% from low-39% from high | |
| 47Moderate | Travere Therapeutics, Inc. | $104k 5,192 shares | -5% | - | |
| 37Weak | Travere Therapeutics, Inc. | $16k 865 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $17.44 | $349k | 138,016 | 25 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -27,473 | $62.00 | $1.7M | 110,543 | 25 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -20,735 | $62.61 | $1.3M | 89,808 | 25 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,900 | $63.69 | $121k | 87,908 | 25 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -400 | $65.31 | $26k | 87,508 | 25 d ago |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 2, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock | -642 | $66.37 | $43k | 118,016 | 39 d ago |
| Sep 3, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -454 | $18.20 | $8,263 | 92,202 | Sep 5, 2025 |
| Sep 4, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -119 | $19.71 | $2,345 | 92,083 | Sep 5, 2025 |
| Aug 27, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -470 | $17.31 | $8,136 | 92,656 | Aug 28, 2025 |
| May 2, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock | +4,920 | - | - | 94,910 | May 5, 2025 |
| May 5, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock | -1,784 | $21.05 | $38k | 93,126 | May 5, 2025 |
| May 2, 2025 | TVTX Travere Therapeutics, Inc. | MOption exercise Performance-based restricted stock unitsderivative | -4,920 | $0.00 | $0 | 4,920 | May 5, 2025 |
| Apr 11, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock | -48 | $13.14 | $631 | 89,990 | Apr 14, 2025 |
| Jan 31, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock | +21,500 | $0.00 | $0 | 95,230 | Feb 4, 2025 |
| Feb 3, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock | -5,192 | $20.12 | $104k | 90,038 | Feb 4, 2025 |
| Jan 31, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Employee stock option (right to buy)derivative | +58,000 | $0.00 | $0 | 58,000 | Feb 4, 2025 |
| Jan 22, 2025 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock | -865 | $18.94 | $16k | 73,730 | Jan 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.